scholarly journals Proportion of Patients Pulmonary Cancer With History of Slow Diagnosis Due to Diagnosis as Lung Tuberculosis

2019 ◽  
Vol 39 (2) ◽  
pp. 92-102
Author(s):  
Cut Yulia Indah Sari ◽  
Faisal Yunus ◽  
Elisna Sjahruddin
Keyword(s):  
Lung Cancer ◽  
Pulmonary Tuberculosis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Diagnosis Delay ◽  
X Rays ◽  
Small Cell Lung ◽  
Study Objective ◽  
Pulmonary Tb

Background: In tuberculosis (TB) endemic countries, the diagnosis delay in lung cancer is due to initially misdiagnosed as pulmonary tuberculosis. The major concern that rose since early diagnosis of lung cancer could improve survival by tumor resectability chance and chemo-radiotherapy modality options. This study objective was to find out the proportion of lung cancer diagnosis delay due initially to misdiagnosed as pulmonary TB. Method: The cross-sectional study was held in Persahabatan Hospital and the subjects were histopatologically proven lung cancer patients between September 2012 to February 2013 involving totally 100 patients. The diagnosis delay were determined as whether the patients had been diagnosed as pulmonary tuberculosis and received anti-tuberculosis treatment (ATT) more than one month since current symptoms onset. All patients were interviewed and all chest X-rays were documented. Results: Fourty one of 100 patients were diagnosed as pulmonary TB and 29 of 41 patients received ATT more than one month. It consisted of 21 men and 8 women with the mean age of 51.5 years old. The cytology and histopatological biopsy revealed 28 Non Small Cell Lung Cancer (NSCLC) cases, and One Small Cell Lung Cancer (SCLC) case with all case were in end stage condition (6 cases in stage III and 22 cases in stage IV). Pre-referral sputum Acid Fast Bacilli (AFB) was conducted in only 9 cases with all negative results. Mean duration of ATT taken was 4.5±0.4 months. The ATT were given by 13 general practitioners, 12 pulmonologists and 4 internists. Discussion: Similar radiological findings in highly incidence of pulmonary TB could cause a large number of diagnosis delay in lung cancer due to initially diagnosed as pulmonary tuberculosis. Without proper investigation based on International Standard of TB Care, starting ATT with inadequate evaluation leads to diagnosis delay and lung cancer progression. (J Respir Indo 2019; 39(2))

scholarly journals A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient

2021 ◽  
pp. 659-663
Author(s):  
Caibao Jin ◽  
Bin Yang
Keyword(s):  
Lung Cancer ◽  
Pulmonary Tuberculosis ◽  
Cancer Patient ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Lung Cancer Patient ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pulmonary Tb ◽  
Egfr Mutant

The coexistence of lung cancer and pulmonary tuberculosis (TB) is rare, and the clinical and radiological features are always similar between lung cancer and pulmonary TB. In the present case, a non-small cell lung cancer patient with an epidermal growth factor receptor (EGFR)-sensitive mutation was diagnosed with pulmonary TB during the treatment of tyrosine kinase inhibitor (TKI) because of the discrepant and confusing responses among different lesions. Therefore, we should combine clinical and radiological characteristics with pathological and microbiological tests to confirm the diagnosis of TB or lung cancer. It is a safe and selectable therapeutic strategy to treat EGFR mutant lung cancer patients with active TB using anti-TB medications and TKIs simultaneously.

Exhaustive Review on Lung Cancers: Novel Technologies

2019 ◽  
Vol 15 (9) ◽  
pp. 873-883
Author(s):  
Sajad Khan ◽  
Shahid Ali ◽  
Muhammad
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Therapy ◽  
Small Cell ◽  
X Rays ◽  
Small Cell Lung ◽  
Microscopic Appearance ◽  
Lung Cancers ◽  
Novel Technologies

Background:Lung cancers or (Bronchogenic-Carcinomas) are the disease in certain parts of the lungs in which irresistible multiplication of abnormal cells leads to the inception of a tumor. Lung cancers consisting of two substantial forms based on the microscopic appearance of tumor cells are: Non-Small-Cell-Lung-Cancer (NSCLC) (80 to 85%) and Small-Cell-Lung-Cancer (SCLC) (15 to 20%).Discussion:Lung cancers are existing luxuriantly across the globe and the most prominent cause of death in advanced countries (USA & UK). There are many causes of lung cancers in which the utmost imperative aspect is the cigarette smoking. During the early stage, there is no perspicuous sign/symptoms but later many symptoms emerge in the infected individual such as insomnia, headache, pain, loss of appetite, fatigue, coughing etc. Lung cancers can be diagnosed in many ways, such as history, physical examination, chest X-rays and biopsy. However, after the diagnosis and confirmation of lung carcinoma, various treatment approaches are existing for curing of cancer in different stages such as surgery, radiation therapy, chemotherapy, and immune therapy. Currently, novel techniques merged that revealed advancements in detection and curing of lung cancer in which mainly includes: microarray analysis, gene expression profiling.Conclusion:Consequently, the purpose of the current analysis is to specify and epitomize the novel literature pertaining to the development of cancerous cells in different parts of the lung, various preeminent approaches of prevention, efficient diagnostic procedure, and treatments along with novel technologies for inhibition of cancerous cell growth in advance stages.

scholarly journals Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer

2018 ◽  
Vol 57 (8) ◽  
pp. 1127-1128 ◽  
Author(s):  
Kristian Hastoft Jensen ◽  
Gitte Persson ◽  
Anna-Louise Bondgaard ◽  
Mette Pøhl
Keyword(s):  
Lung Cancer ◽  
Pulmonary Tuberculosis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Tuberculosis Following PD-1 Inhibitor in A Patient with Non-Small Cell Lung Cancer; A Case Report & Literature Review

2020 ◽  
Author(s):  
Nabil Omar
Keyword(s):  
Lung Cancer ◽  
Pulmonary Tuberculosis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
High Grade Fever ◽  
History Of

Immune checkpoint inhibitors (ICIs) – anti-programmed death-1 (PD-1) and their ligands (PD-L1 and PD-L2) have become widely used in the treatment of several malignancies. Many immune-related adverse events have been linked to these agents. However, tuberculosis (TB) reactivation during their use is increasingly reported. Herein, we present a 58-year-old lady with advanced non-small cell lung cancer (NSCLC) ALK-negative, EGFR wild, and PD-L1 Immune histochemistry (IHC) strongly positive in 95% of tumor cells. The patient presented with high-grade fever and a history of productive cough for a 1-week duration. A few days later, she was diagnosed with pulmonary tuberculosis following the 6th cycle of Pembrolizumab, an anti-PD-1 monoclonal antibody. AFB smear and TB PCR from BAL were positive (rifampin resistance not detected), and she was accordingly started on Anti-TB medications. Immunotherapy was held. Of note, the patient had a history of sick contact with a patient with active TB infection ten years ago, but there was no documentation of latent TB or previous TB infection. Her HIV status is negative. Her sputum AFB smear continued to be positive after four weeks of anti-TB medications. Later, the patient was discharged after her sputum was cleared from AFB (negative x 2 sets). We assumed that our patient developed reactivation of pulmonary tuberculosis secondary to an immune checkpoint inhibitor (Pembrolizumab). She was not re-challenged with Pembrolizumab following TB diagnosis. To our knowledge, this is the first reported case from the Arab and the Middle East; it reinforces the previous observations of the association between ICIs administration and the development of MTB. Nevertheless, further studies in the clinical setting are necessary to establish the exact mechanism involved in this association. Oncologists' awareness & prompt recognition of this potential hazardous consequence are essential. Since there is no clear evidence whether LTBT prior PD-1/PD targeted immunotherapy is required, targeted LTBT before starting ICIs immunotherapy with TB chemoprophylaxis; yet to be explored, particularly in the regions where the MTB prevalence is high.

scholarly journals Діагностика та хірургічне лікування поєднаних форм туберкульозу і раку легень

2018 ◽  
pp. 28-37
Author(s):  
Yu. F. Koshak ◽  
Yu. F. Savenkov
Keyword(s):  
Lung Cancer ◽  
Surgical Treatment ◽  
Pulmonary Tuberculosis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Comparison Groups ◽  
Surgical Tactics ◽  
Made In

The aim of the work: to raise efficiency of the surgical treatment of patients with combined forms of pulmonary tuberculosis and non-small cell lung cancer. Materials and Methods. The retrospective analysis was conducted to 91 patient with combined forms of pulmonary tuberculosis and lung cancer, who were treated in TB hospitals, surgical departments of different regions of Ukraine. Results and Discussion. The analysis of the morphological features of combined forms of pulmonary tuberculosis and non-small cell lung cancer was made in comparison groups , that were explored retrospectively. Conclusion. The leading effect of pulmonary tuberculosis on the surgical treatment of patients with combined forms of tuberculosis and lung cancer was shown in groups of comparison. The increase of 3 years survival in patients of basic groups is set , demonstrating the advantage of active surgical tactics of sterno-mediastinal access and the appliance of more radical bilateral lymph node dissection.

scholarly journals Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review

2020 ◽  
Author(s):  
Aasir M. Suliman ◽  
Shaza A. Bek ◽  
Mohamed S. Elkhatim ◽  
Ahmed A. Husain ◽  
Ahmad Y. Mismar ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pulmonary Tuberculosis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Cancer Case ◽  
Small Cell Lung ◽  
Latent Tb

Abstract Immune checkpoint inhibitors (ICIs)—anti-programmed death-1 (PD-1) and their ligands (PD-L1 and PD-L2) have become widely used in the treatment of several malignancies. Many immune-related adverse events (irAEs) have been linked to these agents. Nonetheless, tuberculosis (TB) reactivation during their use is increasingly recognized and reported. Herein, we present a 58-year-old lady with advanced non-small cell lung cancer (NSCLC) ALK-negative, EGFR wild, and PD-L1 immune histochemistry (IHC) strongly positive in 95% of tumor cells, on ongoing treatment with Pembrolizumab as a first-line monotherapy. Our patient presented with 1-week history of productive cough and high-grade fever. Further workup yielded the diagnosis of pulmonary tuberculosis after her Pembrolizumab sixth cycle with positive AFB smear and TB PCR from BAL (rifampin resistance not detected), with negative HIV status. Hence, immunotherapy was held, and patient was commenced on anti-TB regimen. History revealed contact with active TB patient over the past decade, without previous documentation of latent TB or previous TB infection. Her sputum AFB smear remained persistently positive 4 weeks through anti-TB regimen course. Later, the patient was discharged after her sputum was cleared from AFB (two negative sets). In light of pembrolizumab mechanism of action as an immune checkpoint inhibitor, we suspected its implication on reactivating latent TB which was observed in our patient demonstrating features of pulmonary tuberculosis. She was not re-challenged with Pembrolizumab following TB diagnosis.

scholarly journals Silencing of lncRNA H19 Enhances the Sensitivity to X-rays and Carbon-Ions Through the miR-130a-3p /WNK3 Signal Axis in Non-Small-Cell Lung Cancer Cells

2021 ◽  
Author(s):  
Xueshan Zhao ◽  
Xiaodong Jin ◽  
Qiuning Zhang ◽  
Ruifeng Liu ◽  
Hongtao Luo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Therapeutic Target ◽  
Ion Irradiation ◽  
Expression Profiles ◽  
Small Cell ◽  
X Rays ◽  
Small Cell Lung ◽  
Carbon Ion

Abstract Background: LncRNA H19 was believed to act as an oncogene in various types of tumors and was considered to be a therapeutic target and diagnosis marker. However, the role of lncRNA H19 in regulating the radiosensitivity of non-small cell lung cancer (NSCLC) cells was unknown. However, the effects of lncRNA H19 on radiosensitivity of NSCLC were not clear. Methods: The expression profiles of lncRNAs were explored via transcriptome sequencing in NSCLC. The CCK-8, EDU, and clonogenicity survival assay were conducted to explore the proliferation and radiosensitivity in NSCLC cells. Results: Expression patterns of lncRNAs revealed that compared with A549 cells, lncRNA H19 was upregulated in radioresistant NSCLC(A549-R11) cells. Knockdown experiments revealed that lncRNA H19 enhanced the radiation sensitivity of both A549 and H460 cancer cell lines to X-rays and carbon ion irradiation. Mechanistically, lncRNA H19 upregulated With-No-Lysine Kinase 3 (WNK3) expression via serving as a sponge of miR-130a-3p and promoted the resistance of NSCLC cells to both X-rays and carbon ion irradiation. Conclusion: Knockdown of lncRNA H19 promoted the radiation sensitivity of NSCLC cells to X-rays and carbon ion irradiation. Hence, lncRNA H19 might function as a potential therapeutic target which enhance the anti-tumor effects of radiotherapy in NSCLC.

Sign in / Sign up

Export Citation Format

Share Document